Wright Medical Group (WMGI) Tops Q4 EPS by 21c, Beats on Revenues; Offers FY18 Revenue Mid-Point Outlook Below Consensus

Note: EPS may not be comparable

Wright Medical Group (NASDAQ: WMGI) reported Q4 EPS of $0.25, $0.21 better than the analyst estimate of $0.04. Revenue for the quarter came in at $218 million versus the consensus estimate of $215.15 million.

• Fourth Quarter 2017 Net Sales of $218 Million; Full-Year 2017 Net Sales of $745 Million
• Net income from continuing operations for the fourth quarter of 2017 totaled $26.9 million, or $0.25 per diluted share
• Fourth Quarter 2017 Net Income From Continuing Operations of $27 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of $38 Million
• Full-Year 2017 Net Loss from Continuing Operations of Negative $65 Million; Non-GAAP Adjusted EBITDA From Continuing Operations of Positive $88 Million
• U.S. Upper Extremities Business Increased 29%, Led by Ongoing Launch of PERFORM™ Reversed Glenoid
• Company Provides Full-Year 2018 Net Sales Guidance of $800 Million to $812 Million
• Company Provides Full-Year 2018 Non-GAAP Adjusted EBITDA Guidance of $104 Million to $111 Million

Outlook

The company anticipates net sales for full-year 2018 of approximately $800 million to $812 million. This guidance range has approximately 1% cushion from foreign currency exchange rates as compared to current rates. In addition, this range implies full-year 2018 constant currency net sales growth of 9% to 11%, excluding the estimated $9 million impact of the four fewer selling days in fourth quarter of 2018.

GUIDANCE:

Wright Medical Group sees FY2018 revenue of $800-812 million, versus the consensus of $808.95 million.

For earnings history and earnings-related data on Wright Medical Group (WMGI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c